Pulse Biosciences, Inc. (NASDAQ:PLSE) Short Interest Down 18.1% in November

Pulse Biosciences, Inc. (NASDAQ:PLSE) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 2,080,000 shares, a drop of 18.1% from the October 31st total of 2,540,000 shares. Approximately 12.2% of the shares of the stock are short sold. Based on an average trading volume of 169,800 shares, the days-to-cover ratio is presently 12.2 days.

Pulse Biosciences Stock Performance

PLSE opened at $21.40 on Monday. Pulse Biosciences has a twelve month low of $6.59 and a twelve month high of $22.69. The firm’s 50-day moving average price is $17.31 and its 200 day moving average price is $15.88.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the previous year, the firm posted ($0.19) earnings per share.

Institutional Trading of Pulse Biosciences

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new stake in Pulse Biosciences during the first quarter worth $88,000. Quest Partners LLC purchased a new position in Pulse Biosciences during the second quarter worth about $91,000. Cetera Advisors LLC acquired a new stake in shares of Pulse Biosciences during the first quarter valued at about $109,000. Rhumbline Advisers raised its stake in shares of Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares during the period. Finally, Franklin Resources Inc. acquired a new position in shares of Pulse Biosciences in the 3rd quarter worth approximately $378,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Wednesday, November 27th.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.